Ken Griffin Sarepta Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 308,000 shares of SRPT stock, worth $32.2 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
308,000
Previous 386,100
20.23%
Holding current value
$32.2 Million
Previous $61 Million
36.94%
% of portfolio
0.01%
Previous 0.01%
Shares
29 transactions
Others Institutions Holding SRPT
# of Institutions
532Shares Held
84.5MCall Options Held
2.06MPut Options Held
1.52M-
Black Rock Inc. New York, NY10.3MShares$1.08 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.97MShares$937 Million0.02% of portfolio
-
Capital International Investors Los Angeles, CA6.26MShares$654 Million0.16% of portfolio
-
Janus Henderson Group PLC London, X04.36MShares$456 Million0.29% of portfolio
-
State Street Corp Boston, MA4.27MShares$446 Million0.02% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $9.15B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...